

Notes of the Formulary Management Group

Held on	Tuesday 2 nd September 2016			Jubilee House, Room 1	
Members	Attended	Apologies	Absent	Designation	Abbreviation
	✓			Head of Medicines Management (Chair)	(C)
		✓		Prescribing Adviser	(PA)
	✓			GP Lead for Medicines Management	(GP)
	✓			WHT Pharmacist	(WHTP)
	✓			Primary Care Pharmacist	(PCP)
	✓			Clinical Nurse Specialist	(CNS)
			✓	Nurse Non-Medical Prescriber	(NNMP)
		✓		DWMHPT Pharmacist	(DWMHPT)
	✓			DWMHPT Deputy Pharmacist	(DWMHDP)
	✓			Healthcare Governance	(HG)
			✓	Chief Pharmacist Walsall Healthcare Trust	(CPWHT)
			✓	District Nurse Team Leader Walsall Healthcare Trust	(DNTL)
	✓			Patient Representative	(PR)
	✓			Note Taker	
	✓			LMC	
	✓			SPR	

	Agenda item	Actions
1	<p><u>Welcome And Apologises (Declarations of AOB)</u></p> <p>Everyone was welcomed to Septembers Formulary Management Group meeting.</p>	
2	<p><u>Minutes Of Last Meeting</u> - Consent agenda accepted.</p> <p>The minutes from the last meeting in August were declared a true and accurate record.</p>	
3	<p><u>Matters Arising/Actions Sheet</u></p> <p>Degludec – C has re-requested the audit from the trusts consultant of Endocrinology & Diabetes Mellitus and confirmed the audit was sent to PA.</p> <p>ACTION - C to chase audit with PA and agreed to send the document onto the committee for an overview.</p> <p>Ferinject – A Complex discussion took place with the committee regarding the drug. Issues were raised to the Dr and the following suggestions were put forward to him:</p> <ul style="list-style-type: none"> • The presented audit requires amendments and a proposed name change ‘Follow up Management Plan’ was made for the GPs. • A suggestion for a clinical audit to be produced, with discussions of secondary care and the financial consequences. <p>Following on from that, it was agreed by the committee to not accept the drug on this occasion and proposed the consultant bring back the application to the next JMMC meeting following the suggested improvements by the committee.</p> <p>ABX Formulary – C to chase for updates. Proposed date for completion end of year 2016.</p> <p>NOACs - PCP confirmed the document was forwarded onto the Dr who is currently engaged at present but confirmed the paperwork is in hand.</p> <p>KEELE Competency Training – C to chase up and will come back to the committee with an update in</p>	

Next Meeting – Tuesday 4th October 2016, 1:00 – 3:30pm at Jubilee House, Room 1

Notes of the Formulary Management Group

	<p>due course.</p> <p>Quarterly Declarations of Interest – Completed by the committee.</p> <p>Vortioxetine – DWMHDP confirmed the audit will be ready in October.</p> <p>Baby Milks Formulary – C confirmed further work required.</p> <p>Obesity Drugs – The Dr has been invited to attend the next committee meeting.</p> <p>Renal Function and RAS Drug Combinations – C contacted the Dr for clarity, currently awaiting a response from him.</p> <p>OPEP Funding – C to re-request the pathway.</p> <p>Guanfacine (Revised ESCA) – C agreed this now a completed action.</p> <p>Gevoxa – C agreed this was a completed action.</p> <p>Adult ADHD Shared Care Protocol – C will be sending onto the Senior Commissioning Development Manager for further guidance going forward – Protocol still to be approved.</p> <p>Branded Lamotrigine/Lamictal – On-going discussions are currently taking place – Further updates to follow.</p> <p>Optimize RX – C to chase up with MOP regarding updates.</p> <p>Do Not Prescribe List – A Draft list has been developed - It was agreed the CCG/Quality team will produce a survey and distribute to various departments to provide their professional opinion.</p> <p>Denosumab for male Osteoporosis – A discussion took place and the committee agreed a full application was required along with further advice.</p>	
4	<p><u>Declarations of Interest</u></p> <p>A committee member provided the CCG with their declaration of interest form.</p>	
5	<p><u>NICE Technology Appraisal</u></p> <p>Praluent – A complex discussion took place and the committee agreed a strict criteria needs to be agreed regarding the pathway, prescribing and follow-up.</p> <p><u>ACTION</u> – C to email the Dr and PA to contact the consultant and agree Blutec pathway.</p> <p>Sacubitril – (WHTP) A quick discussion took place and the committee approved the drug.</p>	
6	<p><u>Non NICE TA Drugs/Devices – Full Applications</u></p> <p>Odesfey - A quick discussion took place and the committee approved the drug.</p>	
7	<p><u>Non – NICE TA Drug/Devices - Short Applications</u></p> <p>Butec (Buprenorphine patches) – The cost implications were brought to the meeting and the drug was approved.</p> <p>Symbicort – A quick discussion took place and the clarifications were confirmed and the drug was approved.</p>	

Notes of the Formulary Management Group

8	<p><u>Drug Safety Update- June</u></p> <p>Riociguat - A brief discussion took place with the committee regarding the above drug safety update; full details can be found in the folder.</p>	
9	<p><u>Horizon Scanning</u></p> <p>NICE Forward Planner – A quick discussion took place.</p>	
10	<p><u>Appeals</u></p> <p>None</p>	
11	<p><u>Formulary Updates</u></p> <p>None</p>	
12	<p><u>Formulary Breach</u></p> <ul style="list-style-type: none"> • Victoza • Liraglutide <p>A discussion took place regarding the two above drug breaches and the committee agreed to invite the Dr to the next meeting and explain to the committee the reasoning behind prescribing these drugs.</p>	
13	<p><u>Recommendations to JMMC</u></p> <p>None</p>	
14	<p><u>Any Other Business</u></p> <ul style="list-style-type: none"> • KINES Liraglutide – Was not discussed • JMMC Future – It was agreed by the JMMC committee to not join with another APC (Area Prescribing Committee). C advised the committee that a piece of work will follow in due course following the committee’s decision to stay as Walsall. All sections of Formulary to be reviewed as Sub-groups. Recommendation to come into the Formulary and then passed on the JMMC. Sub-Groups will be determined as per speciality. • KINES Safety of Reducing Antibiotic Prescribing for RTIs – Was not discussed • KINES Monthly update Jul 16 - Was not discussed 	
15	<p>Finish</p>	<p>15:15</p>
<p>These minutes are a true representation of the Group’s proceeding</p> <p>Signed: _____ Chair _____ Date _____</p>		

These minutes will be redacted to remove names/initials before publication

Notes of the Formulary Management Group

Future Meeting Dates

Formulary Management Group Future Meeting Schedule 2016								
Date	Month	Year	Venue		Date	Month	Year	Venue
					4 th	October	2016	Room1
					1 st	November	2016	Room1
					6 th	December	2016	Room1

Formulary Management Group Future Meeting Schedule 2017								
Date	Month	Year	Venue		Date	Month	Year	Venue
3 rd	January	2017	Room1		4 th	July	2017	Room1
7 th	February	2017	Room1		1 st	August	2017	Room1
7 th	March	2017	Room1		5 th	September	2017	Room1
4 th	April	2017	Room1		3 rd	October	2017	Room1
2 nd	May	2017	Room1		7 th	November	2017	Room1
6 th	June	2017	Room1		5 th	December	2017	Room1

Formulary Management Group Future Meeting Schedule 2018								
Date	Month	Year	Venue		Date	Month	Year	Venue
2 nd	January	2018	Room1		3 rd	July	2018	Room1
6 th	February	2018	Room1		7 th	August	2018	Room1
6 th	March	2018	Room1		4 th	September	2018	Room1
3 rd	April	2018	Room1		2 nd	October	2018	Room1
1 st	May	2018	Room1		6 th	November	2018	Room1
5 th	June	2018	Room1		4 th	December	2018	Room1

Next Meeting – Tuesday 4th October 2016, 1:00 – 3:30pm at Jubilee House, Room 1